SOLICITATION NOTICE
R -- Professional Services Contract - Statement of Work
- Notice Date
- 1/13/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(DE)-2011-073-JML
- Archive Date
- 2/3/2011
- Point of Contact
- Jonathan M. Lear, Phone: 3014514470
- E-Mail Address
-
learj@nhlbi.nih.gov
(learj@nhlbi.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work in accordance with the Notice of Intent. THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisitions (OA), on behalf of the National Institute of Dental and Craniofacial Research (NIDCR), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Dr. Maria Gliozzi, 2206 Wyoming Ave, NW, Washington, DC 20008-3908 to provide Professional Services in the Cellular and Clinical Immunology Section, NIDCR. Dr. Gliozzi will provide professional laboratory services utilizing human and animal model specimens to explore the relationship between protease inhibitors, such as secretory leukocyte protease inhibitor and proteases, including elastase and plasmin, which are key enzymes that participate in the inappropriate and unregulated pericellular proteolysis involved in degradation of the basement membrane and adjacent extracellular matrix (ECM). These pathways are instrumental not only in the tissue destruction linked to chronic inflammation and autoimmunity, but also to the invasive program of tumor cells, and particularly associated with a negative prognosis in head and neck squamous cell carcinomas (HNSCC). Membrane annexin A2 not only serves as a docking station for plasminogen activation, but as a binding sire for an inhibitor of the process. Plasmin, in turn, activates multiple downstream matrix-degrading metalloproteinases (MMPs) that are produced by tumor cells as well as stromal cells, including macrophages, providing the cell with the necessary enzymatic machinery to break down and invade surrounding tissue structure. Dr. Gliozzi will perform experiments in an effort to define the tissue destructive pathways in inflammatory diseases and the negative prognosis of HNSCC. By immunochemistry and immunofluorescence techniques, in addition to molecular analyses, Dr. Gliozzi will define these relationships and their contribution to inflammation and to human and mouse cancer. Dysregulation of the protease/anti-protease balance underlies tissue destruction and tumor cell invasion, warranting examination of potential deficiencies in anti-proteases as contributors to metastatic events. The sole source determination is based on the fact that Dr. Gliozzi has received critical expertise in oral diseases, including the autoimmune disease known as Sjogren's syndrome, which attacks the salivary glands, as well as systemic targets and has severe consequences in those affected. She is also an authority on oral cancer and the studies in which she will be involved require expertise on the immunopathogenesis of head and neck cancer, which is one of the top ten cancers in the United States. It is imperative to have an individual who already has the expertise in this area to perform the experiments in a timely fashion. Recruiting an individual lacking this pivotal expertise would be extremely detrimental to the clinical and patient studies involved. The period of performance is 12 months. The delivery point is the National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD. The North American Industry Classification System (NAICS) Code is 541711, Research and Development in Biotechnology, and is not a small business set aside. The acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, therefore the requirements of FAR Part 6, Competitive Requirements, are not applicable and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-48 (December 30, 2010). Interested parties may identify their interest and capabilities in response to this synopsis by January 19, 2011 at 3:00pm Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurements. Inquiries to this announcement, referencing synopsis number NHLBI-CSB-(DE)-2011-073-JML, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisitions, COAC Services Branch, 6701 Rockledge Drive, Room 6151, Bethesda, Maryland 20892-7902, Attention: Jonathan Lear. Responses may be submitted electronically to learj@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(DE)-2011-073-JML/listing.html)
- Place of Performance
- Address: National Institutes of Health/NIDCR, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02359655-W 20110115/110113234309-e4ab77bcf9099677633221d1c2bf7737 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |